Özbek-Uzman Selma, Yalnız-Akkaya Züleyha, Şingar Özdemir Evin, Burcu Ayşe
Department of Ophthalmology, Ankara Training and Research Hospital, University of Health Science, Ankara, Turkey.
Eur J Ophthalmol. 2022 Jul;32(4):2159-2165. doi: 10.1177/11206721211048372. Epub 2021 Sep 29.
We aimed to investigate the efficacy and safety of single-dose autologous serum eye drops (ASEDs) for treatment of persistent corneal epithelial defects (PEDs).
About 34 eyes of 26 patients treated from March 2016 to May 2020 with a single dose of ASEDs for PEDs that did not respond to conventional treatment were retrospectively evaluated. Patient demographics, predisposing factors, size, and duration of the PED, duration of treatment, and dosage of ASEDs, PED healing time, success rate of the ASED treatment, and follow-up time after the onset of ASED treatment were recorded. Autologous serum eye drops (20%) were prepared by diluting the serum with preservative-free artificial tears in single-dose vials. Vials were stored at -20°C and used daily after dissolving.
The mean patient age was 47.0 ± 18.5 years, and 13 (50%) of the patients were male. The most common indication for ASEDs was PED after keratoplasty. The mean duration of ASED treatment was 8.5 ± 6.3 months, and mean follow-up time was 22.8 ± 12.2 months. Autologous serum eye drop treatment was effective in 25 (73.5%) eyes and partially effective in 5 (14.7%) eyes. None of the eyes displayed complications related to the treatment.
In patients with PED for whom conservative treatment is insufficient, ASEDs prepared by dilution with preservative-free artificial tears in single-dose vials and administered based on the daily use principle appear to be effective and safe.
我们旨在研究单剂量自体血清滴眼液（ASEDs）治疗持续性角膜上皮缺损（PEDs）的疗效和安全性。
回顾性评估2016年3月至2020年5月期间，26例患者的34只眼睛，这些眼睛因PEDs接受单剂量ASEDs治疗，且对传统治疗无反应。记录患者的人口统计学信息、诱发因素、PEDs的大小和持续时间、治疗持续时间、ASEDs的剂量、PED愈合时间、ASEDs治疗成功率以及ASEDs治疗开始后的随访时间。通过将血清与无防腐剂的人工泪液在单剂量小瓶中稀释来制备自体血清滴眼液（20%）。小瓶储存在-20°C，溶解后每日使用。
患者的平均年龄为47.0±18.5岁，13例（50%）患者为男性。ASEDs最常见的适应证是角膜移植术后的PEDs。ASEDs治疗的平均持续时间为8.5±6.3个月，平均随访时间为22.8±12.2个月。自体血清滴眼液治疗在25只（73.5%）眼睛中有效，在5只（14.7%）眼睛中部分有效。所有眼睛均未出现与治疗相关的并发症。
对于保守治疗不足的PEDs患者，用无防腐剂的人工泪液在单剂量小瓶中稀释制备并基于每日使用原则给药的ASEDs似乎是有效且安全的。
